RU2018125514A - Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента - Google Patents
Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента Download PDFInfo
- Publication number
- RU2018125514A RU2018125514A RU2018125514A RU2018125514A RU2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A RU 2018125514 A RU2018125514 A RU 2018125514A
- Authority
- RU
- Russia
- Prior art keywords
- ahus
- factor
- developing
- use according
- subject
- Prior art date
Links
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title claims 6
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title claims 6
- 230000001419 dependent effect Effects 0.000 title claims 3
- 230000004913 activation Effects 0.000 title 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000024203 complement activation Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108010053085 Complement Factor H Proteins 0.000 claims 2
- 102000003712 Complement factor B Human genes 0.000 claims 2
- 108090000056 Complement factor B Proteins 0.000 claims 2
- 102100035432 Complement factor H Human genes 0.000 claims 2
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 claims 2
- 101710101162 Complement factor H-related protein 4 Proteins 0.000 claims 2
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 230000000977 initiatory effect Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 102000016918 Complement C3 Human genes 0.000 claims 1
- 108010028780 Complement C3 Proteins 0.000 claims 1
- 102100040132 Complement factor H-related protein 1 Human genes 0.000 claims 1
- 101710101151 Complement factor H-related protein 1 Proteins 0.000 claims 1
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 claims 1
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000002506 anticoagulant protein Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 238000002716 delivery method Methods 0.000 claims 1
- 108010071253 factor H-related protein 1 Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
Claims (12)
1. Применение MASP-2-ингибирующего агента, который ингибирует MASP-2-зависимую активацию комплемента, при изготовлении лекарственного средства для лечения субъекта, страдающего от или подверженного риску развития атипичного гемолитического уремического синдрома (aHUS), где MASP-2-ингибирующий агент представляет собой ингибирующее моноклональное антитело против MASP-2 или его антигенсвязывающий фрагмент, которые специфически связываются с частью SEQ ID NO:6 и селективно ингибируют MASP-2-зависимую активацию комплемента без по существу ингибирования C1q-зависимого пути комплемента.
2. Применение по п.1, где перед введением лекарственного препарата субъект, как определено, проявляет один или более симптомов, выбранных из группы, состоящей из (i) анемии, (ii) тромбоцитопении, (iii) почечной недостаточности и (iv) увеличивающегося креатинина, и лекарственное средство составляют для введения эффективного количества в течение временного периода для улучшения указанного одного или более симптомов.
3. Применение по п.1, где субъект страдает от или подвержен риску развития фактор H-независимого aHUS.
4. Применение по п.1, где субъект страдает от aHUS, связанного с фактором I, фактором B или мембранным кофактором CD46.
5. Применение по п. 1, где для субъекта, подверженного риску развития aHUS, определено наличие генетического маркера, связанного, как известно, с повышенным риском развития атипичного гемолитического уремического синдрома (aHUS).
6. Применение по п.6, где генетический маркер, связанный, как известно, с повышенным риском развития aHUS, в гене, выбранном из группы, включающей фактор H комплемента (CFH), фактор I (CFI), фактор B (CFB), мембранный кофактор CD46, C3, фактор H комплемента-родственный белок 1 (CFHR1), антикоагулянтный белок тромбодулин (THBD), фактор H комплемента-родственный белок 3 (CFHR3) и фактор H комплемента-родственный белок 4 (CFHR4).
7. Применение по п.1, где субъект, подверженный риску развития aHUS, испытал событие, связанное, как известно, с инициированием клинических симптомов aHUS.
8. Применение по п.7, где событие, связанное с инициированием клинических симптомов aHUS, выбирают из группы, состоящей из воздействия препарата, инфекции, злокачественного новообразования, повреждения, трансплантата органа и ткани и беременности.
9. Применение по п.8, где инфекция представляет собой бактериальную инфекцию.
10. Применение по п. 1, где субъект страдает от или подвержен риску развития некишечного aHUS, связанного с инфекцией S. pneumonia.
11. Применение по п.1, где лекарственное средство составляют для подкожного введения.
12. Применение по п. 1, где лекарственное средство составляют для введения субъекту через внутривенный катетер или другим способом катетерной доставки.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473698P | 2011-04-08 | 2011-04-08 | |
| US61/473,698 | 2011-04-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013149792A Division RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021103424A Division RU2021103424A (ru) | 2011-04-08 | 2021-02-12 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018125514A true RU2018125514A (ru) | 2019-03-12 |
| RU2018125514A3 RU2018125514A3 (ru) | 2019-10-30 |
| RU2743409C2 RU2743409C2 (ru) | 2021-02-18 |
Family
ID=46966283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125514A RU2743409C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
| RU2013149792A RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013149792A RU2662563C2 (ru) | 2011-04-08 | 2012-04-06 | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8951522B2 (ru) |
| EP (3) | EP2694108B1 (ru) |
| JP (4) | JP5937197B2 (ru) |
| KR (6) | KR102217658B1 (ru) |
| CN (3) | CN107638565B (ru) |
| AU (1) | AU2012239889B2 (ru) |
| BR (1) | BR112013025917A2 (ru) |
| CA (4) | CA2977009C (ru) |
| CL (1) | CL2013002874A1 (ru) |
| DK (2) | DK3287142T3 (ru) |
| ES (2) | ES2894342T3 (ru) |
| IL (3) | IL228758B (ru) |
| MX (3) | MX381987B (ru) |
| NZ (5) | NZ731596A (ru) |
| PL (1) | PL3287142T3 (ru) |
| RU (2) | RU2743409C2 (ru) |
| WO (1) | WO2012139081A2 (ru) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0688182B2 (ja) | 1986-09-08 | 1994-11-09 | バブコツク日立株式会社 | スタツド着脱装置 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR102217658B1 (ko) | 2011-04-08 | 2021-02-22 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| SG11201403416TA (en) | 2011-12-21 | 2014-07-30 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
| ES2670668T3 (es) * | 2012-04-06 | 2018-05-31 | Omeros Corporation | Composiciones y métodos para inhibir la MASP-1 y/o la MASP-3 para el tratamiento de la hemoglobinuria nocturna paroxísmica |
| LT2861246T (lt) * | 2012-06-18 | 2021-04-26 | Omeros Corporation | Masp-1 ir (arba) masp-2, ir (arba) masp-3 slopinimo kompozicijos ir būdai, skirti įvairių ligų ir sutrikimų gydymui |
| EP4613778A2 (en) * | 2012-10-25 | 2025-09-10 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| GB2509260B (en) | 2012-11-02 | 2016-05-04 | True North Therapeutics Inc | Anti-complement C1s antibodies and uses thereof |
| NZ629682A (en) * | 2013-03-15 | 2017-03-31 | Omeros Corp | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| MX389699B (es) * | 2013-10-17 | 2025-03-20 | Omeros Corp | Composiciones que comprenden anticuerpos inhibidores de masp-2 para usarse en el tratamiento de post-trasplante de celulas madre de microangiopatía trombótica (tma). |
| WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| HRP20211561T8 (hr) | 2014-06-12 | 2022-03-04 | Ra Pharmaceuticals, Inc. | Modulacija aktivnosti komplementa |
| PL3250230T3 (pl) | 2015-01-28 | 2022-02-14 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
| LT3280440T (lt) | 2015-04-06 | 2023-02-27 | Bioverativ Usa Inc. | Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai |
| SG11201803834UA (en) | 2015-11-09 | 2018-06-28 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| LT3685847T (lt) | 2015-12-16 | 2023-03-27 | Ra Pharmaceuticals, Inc. | Komplemento aktyvumo moduliatoriai |
| KR20180091097A (ko) | 2015-12-23 | 2018-08-14 | 그리노파티온 바이오테크 게엠베하 | 보체 활성화를 억제하기 위한 폴리펩티드 |
| KR102475622B1 (ko) * | 2016-01-05 | 2022-12-08 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| CA3018774C (en) * | 2016-03-31 | 2023-02-28 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| CR20190223A (es) | 2016-10-12 | 2019-08-21 | Bioverativ Usa Inc | ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| JP6442703B2 (ja) * | 2016-12-26 | 2018-12-26 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
| JPWO2018164186A1 (ja) * | 2017-03-09 | 2020-01-09 | 協和キリン株式会社 | Ｍａｓｐ２の発現を抑制する核酸 |
| KR20190013635A (ko) * | 2017-07-28 | 2019-02-11 | 주식회사 레모넥스 | 간암의 예방 또는 치료용 약학적 조성물 |
| EP3718572B1 (en) | 2017-12-01 | 2024-07-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
| CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110997917B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110945132B (zh) | 2017-12-01 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CA3084043A1 (en) | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| CN112867706B (zh) * | 2018-05-29 | 2024-11-15 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
| EP3842534A4 (en) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID AND METHOD OF USE THEREOF |
| EP3628735A1 (en) | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SHORT INTERFERENT RNA CONJUGATE, METHOD FOR PREPARATION AND USE THEREOF |
| EA202191342A1 (ru) * | 2018-11-15 | 2021-08-10 | Айонис Фармасьютикалз, Инк. | Модуляторы экспрессии irf5 |
| US20230272402A1 (en) * | 2018-12-25 | 2023-08-31 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof |
| US20220160820A1 (en) | 2019-03-08 | 2022-05-26 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| JP7530106B2 (ja) * | 2019-03-14 | 2024-08-07 | レナセラピューティクス株式会社 | Ｉｈｈ発現を調節するための核酸複合体 |
| CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
| CA3137895A1 (en) | 2019-04-24 | 2020-10-29 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| US20240200076A1 (en) * | 2019-05-22 | 2024-06-20 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
| JP7227401B2 (ja) | 2019-11-27 | 2023-02-21 | 京セラ株式会社 | 通信制御方法及びユーザ装置 |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP7721143B2 (ja) | 2019-12-04 | 2025-08-12 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CN115103709A (zh) | 2019-12-04 | 2022-09-23 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| CN115052604A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| WO2021168148A1 (en) * | 2020-02-19 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| CN113674860B (zh) * | 2020-05-15 | 2024-05-17 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、系统及其应用 |
| WO2021231720A1 (en) * | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| IL299048A (en) | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN120173119B (zh) * | 2020-12-16 | 2025-09-30 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| JP2024518724A (ja) * | 2021-04-25 | 2024-05-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途 |
| MX2024007065A (es) | 2021-12-10 | 2024-06-20 | Omeros Corp | Anticuerpos terapeuticos que se unen al dominio de serina proteasa de masp-2 y sus usos. |
| JP2025524967A (ja) * | 2022-07-25 | 2025-08-01 | アムジエン・インコーポレーテツド | ＦＡＭ１３Ａ発現を阻害するためのＲＮＡｉコンストラクト及び方法 |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN119978131B (zh) * | 2025-04-15 | 2025-06-27 | 北京赛斯维德生物科技有限公司 | 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69030172T2 (de) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| EP1140171A4 (en) | 1998-12-15 | 2002-03-13 | Brigham & Womens Hospital | METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| AU779532B2 (en) | 1999-07-21 | 2005-01-27 | Omeros Corporation | Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| RU2002113381A (ru) | 1999-12-02 | 2004-01-27 | Дженс Христиан ДЖЕНСЕНИУС (DK) | MASP-3, комплемент-связывающий фермент и его применение |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| CN1449440A (zh) | 2000-07-13 | 2003-10-15 | 詹斯·C·詹斯尼厄斯 | Masp－2,一种补体固定酶及其用途 |
| EP1416962A4 (en) | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | METHOD FOR IMPROVING THE COGNITIVE FUNCTION |
| WO2003063799A2 (en) | 2002-02-01 | 2003-08-07 | Omeros Corporation | Compositions and methods for systemic inhibition of cartilage degradation |
| AU2003223288A1 (en) | 2002-03-18 | 2003-10-08 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| CA2490007C (en) | 2002-07-19 | 2011-05-24 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| DK1534313T3 (da) | 2002-07-30 | 2013-02-04 | Omeros Corp | Oftalmologiske irrigationsopløsninger og fremgangsmåde |
| ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
| US20060275764A1 (en) | 2002-12-03 | 2006-12-07 | Aarhus Universitet | Method for determining predisposition to manifestation of immune system related diseases |
| CA2515453C (en) | 2003-02-21 | 2013-09-24 | Tanox, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| CN1791614B (zh) * | 2003-03-17 | 2011-01-12 | 财团法人化学及血清疗法研究所 | 含抗von Willebrand因子特异性切割酶的抗体识别的结构域的构建体 |
| SI1625166T1 (sl) | 2003-05-12 | 2015-08-31 | Helion Biotech Aps | Protitelesa masp-2 |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| PT1753456T (pt) | 2004-06-10 | 2016-11-04 | Univ Leicester | Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20070015703A1 (en) * | 2005-06-17 | 2007-01-18 | Denisa Wagner | ADAMTS13-containing compositions having thrombolytic activity |
| ATE487133T1 (de) | 2006-01-27 | 2010-11-15 | Rappaport Family Inst For Res | Verfahren zur blutgerinnungsbestimmung |
| SI2596807T1 (sl) | 2006-03-08 | 2016-03-31 | Archemix Llc | Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj |
| CN104940917A (zh) | 2008-11-10 | 2015-09-30 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| CA2767755C (en) | 2009-07-17 | 2021-10-12 | Rigshospitalet | Inhibitors of complement activation |
| CA2777845C (en) | 2009-10-16 | 2017-08-01 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| CN102958535A (zh) * | 2009-11-05 | 2013-03-06 | 亚力史剑桥公司 | 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗 |
| BR112012022214A2 (pt) | 2010-03-01 | 2017-07-04 | Alexion Pharma Inc | métodos e composições para tratar doença de degos |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| KR102217658B1 (ko) | 2011-04-08 | 2021-02-22 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| RS60541B1 (sr) | 2011-05-04 | 2020-08-31 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| LT2861246T (lt) | 2012-06-18 | 2021-04-26 | Omeros Corporation | Masp-1 ir (arba) masp-2, ir (arba) masp-3 slopinimo kompozicijos ir būdai, skirti įvairių ligų ir sutrikimų gydymui |
| MX389699B (es) | 2013-10-17 | 2025-03-20 | Omeros Corp | Composiciones que comprenden anticuerpos inhibidores de masp-2 para usarse en el tratamiento de post-trasplante de celulas madre de microangiopatía trombótica (tma). |
| SG11201803834UA (en) | 2015-11-09 | 2018-06-28 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| CA3018774C (en) * | 2016-03-31 | 2023-02-28 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| WO2018070521A1 (ja) * | 2016-10-14 | 2018-04-19 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active Active
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/en active
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 MX MX2018005314A patent/MX381987B/es unknown
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko not_active Ceased
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Ceased
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active Active
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active Active
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
- 2012-04-06 CA CA3237802A patent/CA3237802A1/en active Pending
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Ceased
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en not_active Ceased
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 CA CA3076975A patent/CA3076975C/en active Active
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018125514A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| ES2389093T3 (es) | Procedimiento de tratamiento de una enfermedad hemolítica | |
| Jodele et al. | Tackling COVID‐19 infection through complement‐targeted immunotherapy | |
| JP2014530226A5 (ru) | ||
| Cocanour et al. | Management and novel adjuncts of necrotizing soft tissue infections | |
| JP2013533858A5 (ru) | ||
| Kim et al. | Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation | |
| EA201201660A1 (ru) | Очень высокая эффективность антител к cd37 в образцах крови страдающих cll пациентов | |
| RU2013155618A (ru) | Индукция иммунологической толерантности, используя метотрексат | |
| Hernandes et al. | Polymerase delta-interacting protein 2 deficiency protects against blood-brain barrier permeability in the ischemic brain | |
| Holman et al. | Device related infections: are we making progress? | |
| Christensen et al. | The role of neutrophils and G‐CSF in DNFB‐induced contact hypersensitivity in mice | |
| Påhlman et al. | Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1 | |
| JP2010539974A5 (ru) | ||
| Liu et al. | Protective effect of endothelial progenitor cell-derived exosomal microRNA-382-3p on sepsis-induced organ damage and immune suppression in mice | |
| Johnson et al. | Peritoneal dialysis | |
| van Ruler et al. | Has mortality from sepsis improved and what to expect from new treatment modalities: review of current insights | |
| Ma et al. | Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits | |
| WO2012113343A1 (zh) | Il-17抑制剂在制备治疗和/或预防肺损伤的药物中的用途 | |
| JP2020534280A5 (ru) | ||
| Kim et al. | Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus | |
| ES3008062T3 (en) | Composition comprising dnase i for use in a method of preventing the activation of the aim2 inflammasome | |
| Kim et al. | Transplantation in highly HLA-sensitized patients: challenges and solutions | |
| Yang et al. | Infection and Immunodeficiency in Patients With Chronic Kidney Disease: Current Evidence and Potential Preventive Strategies of Chinese Medicine | |
| Xue et al. | Dysfunctional Immune Regulatory System |